NCT05174013

Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK3858279 in Healthy Caucasian, Chinese and Japanese Participants

A Randomised, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, Target Engagement and Immunogenicity of a Single Subcutaneous Dose of GSK3858279 Administered to Healthy Caucasian, Chinese and Japanese Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 33 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 20 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), target engagement (TE) and immunogenicity of GSK3858279 when administered to healthy Caucasian, Chinese and Japanese participants.

Conditions

• Pain

Interventions

Type	Name	Description
DRUG	GSK3858279	GSK3858279 will be administered
DRUG	Placebo	Placebo will be administered

Timeline

• Start date: 2022-02-14
• Primary completion: 2023-02-10
• Completion: 2023-04-17
• First posted: 2021-12-30
• Last updated: 2025-05-15
• Results posted: 2025-05-15

Locations

2 sites across 1 country: Australia